XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.2
REVENUE (Tables)
 6 Months Ended
Jun. 30, 2024
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table summarizes the disaggregation of revenue by nature:
Three Months Ended June 30,Six Months Ended June 30,
Dollars in millions2024202320242023
Net product sales$11,925 $10,917 $23,484 $21,965 
Alliance revenues116 179 250 323 
Other revenues160 130 332 275 
Total Revenues$12,201 $11,226 $24,066 $22,563 
Revenue Recognition Gross-To-Net Adjustments
The following table summarizes GTN adjustments:
Three Months Ended June 30,Six Months Ended June 30,
Dollars in millions2024202320242023
Gross product sales$20,780 $18,111 $40,075 $35,399 
GTN adjustments(a)
Charge-backs and cash discounts(2,843)(2,279)(5,399)(4,370)
Medicaid and Medicare rebates(3,864)(3,143)(6,948)(5,625)
Other rebates, returns, discounts and adjustments(2,148)(1,772)(4,244)(3,439)
Total GTN adjustments(b)
(8,855)(7,194)(16,591)(13,434)
Net product sales$11,925 $10,917 $23,484 $21,965 
(a)    Includes reductions/(increases) to GTN adjustments for product sales made in prior periods resulting from changes in estimates of ($19 million) and $61 million for the three and six months ended June 30, 2024 and $11 million and $98 million for the three and six months ended June 30, 2023, respectively.
(b)    Includes U.S. GTN adjustments of $8.0 billion and $14.9 billion for the three and six months ended June 30, 2024 and $6.4 billion and $11.9 billion for the three and six months ended June 30, 2023, respectively.
Revenue from External Customers by Products and Services
The following table summarizes the disaggregation of revenue by product and region:
Three Months Ended June 30,Six Months Ended June 30,
Dollars in millions2024202320242023
Growth Portfolio
Opdivo$2,387 $2,145 4,465 $4,347 
Orencia948 927 1,746 1,691 
Yervoy630 585 1,213 1,093 
Reblozyl425 234 779 440 
Opdualag235 154 441 271 
Abecma95 132 177 279 
Zeposia151 100 261 178 
Breyanzi153 100 260 171 
Camzyos139 46 223 75 
Sotyktu53 25 97 41 
Augtyro7 — 13 — 
Krazati32 — 53 — 
Other Growth products(a)
341 295 660 575 
Total Growth Portfolio
5,596 4,743 10,388 9,161 
Legacy Portfolio
Eliquis3,416 3,204 7,136 6,627 
Revlimid1,353 1,468 3,022 3,218 
Pomalyst/Imnovid959 847 1,824 1,679 
Sprycel424 458 798 887 
Abraxane231 258 448 497 
Other Legacy products(b)
222 248 450 494 
Total Legacy Portfolio
6,605 6,483 13,678 13,402 
Total Revenues$12,201 $11,226 $24,066 $22,563 
United States$8,801 $7,804 $17,277 $15,756 
International3,224 3,247 6,414 6,477 
Other(c)
176 175 375 330 
Total Revenues$12,201 $11,226 $24,066 $22,563 
(a)    Includes Onureg, Inrebic, Nulojix, Empliciti and royalty revenues.
(b)    Includes other mature brands.
(c)    Other revenues include alliance-related revenues for products not sold by BMS's regional commercial organizations.